JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function.


Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
25 09 2020
Historique:
pubmed: 17 7 2020
medline: 25 5 2021
entrez: 17 7 2020
Statut: ppublish

Résumé

Intercellular tight junctions are crucial for correct regulation of the endothelial barrier. Their composition and integrity are affected in pathological contexts, such as inflammation and tumor growth. JAM-A (junctional adhesion molecule A) is a transmembrane component of tight junctions with a role in maintenance of endothelial barrier function, although how this is accomplished remains elusive. We aimed to understand the molecular mechanisms through which JAM-A expression regulates tight junction organization to control endothelial permeability, with potential implications under pathological conditions. Genetic deletion of JAM-A in mice significantly increased vascular permeability. This was associated with significantly decreased expression of claudin-5 in the vasculature of various tissues, including brain and lung. We observed that C/EBP-α (CCAAT/enhancer-binding protein-α) can act as a transcription factor to trigger the expression of claudin-5 downstream of JAM-A, to thus enhance vascular barrier function. Accordingly, gain-of-function for C/EBP-α increased claudin-5 expression and decreased endothelial permeability, as measured by the passage of fluorescein isothiocyanate (FITC)-dextran through endothelial monolayers. Conversely, C/EBP-α loss-of-function showed the opposite effects of decreased claudin-5 levels and increased endothelial permeability. Mechanistically, JAM-A promoted C/EBP-α expression through suppression of β-catenin transcriptional activity, and also through activation of EPAC (exchange protein directly activated by cAMP). C/EBP-α then directly binds the promoter of claudin-5 to thereby promote its transcription. Finally, JAM-A-C/EBP-α-mediated regulation of claudin-5 was lost in blood vessels from tissue biopsies from patients with glioblastoma and ovarian cancer. We describe here a novel role for the transcription factor C/EBP-α that is positively modulated by JAM-A, a component of tight junctions that acts through EPAC to up-regulate the expression of claudin-5, to thus decrease endothelial permeability. Overall, these data unravel a regulatory molecular pathway through which tight junctions limit vascular permeability. This will help in the identification of further therapeutic targets for diseases associated with endothelial barrier dysfunction. Graphic Abstract: An graphic abstract is available for this article.

Identifiants

pubmed: 32673519
doi: 10.1161/CIRCRESAHA.120.316742
pmc: PMC7508279
doi:

Substances chimiques

CCAAT-Enhancer-Binding Proteins 0
CEBPA protein, human 0
CEBPA protein, mouse 0
CLDN5 protein, human 0
Cell Adhesion Molecules 0
Claudin-5 0
Cldn5 protein, mouse 0
F11R protein, human 0
F11r protein, mouse 0
Receptors, Cell Surface 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1056-1073

Références

Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Blood. 2004 Apr 1;103(7):2744-52
pubmed: 14656889
Haematologica. 2013 Jun;98(6):918-27
pubmed: 23349306
Physiol Rev. 2006 Jan;86(1):279-367
pubmed: 16371600
Acta Neuropathol. 2018 Mar;135(3):311-336
pubmed: 29411111
J Cell Sci. 1997 Sep;110 ( Pt 17):2065-77
pubmed: 9378757
J Cell Biol. 2008 Nov 3;183(3):409-17
pubmed: 18955553
Exp Cell Res. 2004 Oct 15;300(1):202-12
pubmed: 15383327
CNS Neurosci Ther. 2017 Dec;23(12):947-960
pubmed: 28961379
Exp Cell Res. 2003 Nov 1;290(2):275-88
pubmed: 14567987
Physiol Rev. 2004 Jul;84(3):869-901
pubmed: 15269339
J Clin Invest. 2004 Sep;114(5):729-38
pubmed: 15343392
Neurosci Lett. 2020 May 1;726:133664
pubmed: 29966749
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2408-16
pubmed: 16723450
CNS Neurol Disord Drug Targets. 2014;13(8):1413-26
pubmed: 25345514
J Cell Sci. 2007 Jan 1;120(Pt 1):17-22
pubmed: 17182900
Nat Rev Mol Cell Biol. 2004 Apr;5(4):261-70
pubmed: 15071551
J Biol Chem. 2004 Apr 16;279(16):16254-62
pubmed: 14749337
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Int J Clin Exp Pathol. 2014 Sep 15;7(10):7242-8
pubmed: 25400822
Ann Surg Oncol. 2012 Dec;19(13):4330-6
pubmed: 22549289
Biochem J. 2002 Aug 1;365(Pt 3):561-75
pubmed: 12006103
Curr Neuropharmacol. 2008 Sep;6(3):179-92
pubmed: 19506719
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
Cold Spring Harb Perspect Med. 2012 Oct 01;2(10):
pubmed: 23028127
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10634-9
pubmed: 16027360
IEEE Trans Image Process. 1995;4(3):370-8
pubmed: 18289986
J Mol Med (Berl). 2009 Jun;87(6):571-82
pubmed: 19337719
Biochem Biophys Res Commun. 2009 Mar 6;380(2):387-91
pubmed: 19250634
Eur J Cell Biol. 2006 Nov;85(11):1131-44
pubmed: 16959372
Blood. 2004 Apr 15;103(8):3005-12
pubmed: 15070677
J Biol Chem. 2005 Mar 25;280(12):11665-74
pubmed: 15677455
Mol Pharmacol. 2013 Jan;83(1):122-8
pubmed: 23066090
J Neurochem. 2006 May;97(4):922-33
pubmed: 16573646
Eur J Cell Biol. 2000 Oct;79(10):707-17
pubmed: 11089919
Mol Biol Cell. 2009 Apr;20(7):1916-25
pubmed: 19176753
Methods Mol Biol. 2015;1270:321-46
pubmed: 25702127
Int J Gynecol Cancer. 2009 Feb;19(2):208-13
pubmed: 19395995
Biochem Soc Trans. 2008 Apr;36(Pt 2):149-55
pubmed: 18363555
Blood. 2005 Mar 1;105(5):1950-5
pubmed: 15374886
Mol Cell Endocrinol. 2002 Feb 25;188(1-2):15-20
pubmed: 11911941
Ann N Y Acad Sci. 2012 Jun;1257:115-24
pubmed: 22671597
Blood. 2007 Sep 15;110(6):1848-56
pubmed: 17505016
BMC Cell Biol. 2010 Sep 07;11:68
pubmed: 20822540
J Cell Sci. 2000 Jul;113 ( Pt 13):2363-74
pubmed: 10852816
Nat Rev Immunol. 2007 Jun;7(6):467-77
pubmed: 17525755
Mol Med Rep. 2014 Mar;9(3):779-85
pubmed: 24366267
Nat Cell Biol. 2008 Aug;10(8):923-34
pubmed: 18604199
Oncogene. 2017 Sep 14;36(37):5221-5230
pubmed: 28504718
Cell Stem Cell. 2008 Nov 6;3(5):493-507
pubmed: 18983965
Circ Res. 2018 Jan 19;122(2):231-245
pubmed: 29233846
Acta Neuropathol. 2000 Sep;100(3):323-31
pubmed: 10965803
Biochem Biophys Res Commun. 2007 Nov 16;363(2):276-82
pubmed: 17888405
Cell. 1989 Nov 17;59(4):675-80
pubmed: 2573431
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3928-36
pubmed: 17724169
Ups J Med Sci. 2015;120(3):135-43
pubmed: 26220421
J Cell Biol. 1998 Jul 13;142(1):117-27
pubmed: 9660867
Nat Genet. 2001 Mar;27(3):263-70
pubmed: 11242107
Prog Neurobiol. 2018 Feb;161:79-96
pubmed: 29217457
Fluids Barriers CNS. 2012 Nov 09;9(1):23
pubmed: 23140302
Circ Res. 2019 Feb 15;124(4):511-525
pubmed: 30591003
Cell Signal. 2008 Sep;20(9):1608-15
pubmed: 18585005
J Exp Med. 2007 Dec 24;204(13):3067-76
pubmed: 18039951
J Biol Chem. 2008 Mar 14;283(11):6843-53
pubmed: 18195020
J Cell Biol. 2015 Mar 16;208(6):821-38
pubmed: 25753039
J Biol Chem. 2003 Nov 28;278(48):48434-44
pubmed: 12966102
J Cell Biol. 2003 May 12;161(3):653-60
pubmed: 12743111
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Leukoc Biol. 2006 Oct;80(4):714-8
pubmed: 16857733
EMBO Rep. 2011 Apr;12(4):314-20
pubmed: 21372850
J Immunol. 1991 Oct 1;147(7):2122-9
pubmed: 1918946
J Biol Chem. 2009 Jun 26;284(26):17391-403
pubmed: 19423709
J Biol Chem. 2007 May 11;282(19):14515-24
pubmed: 17351296
EMBO Mol Med. 2014 Feb;6(2):239-58
pubmed: 24378569
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6
pubmed: 7690960

Auteurs

Nikolaos Kakogiannos (N)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Laura Ferrari (L)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Costanza Giampietro (C)

EMPA, Swiss Federal Laboratories for Material Science and Technologies, Experimental Continuum Mechanics, Dübendorf, Switzerland (C.G.).

Anna Agata Scalise (AA)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Claudio Maderna (C)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Micol Ravà (M)

Experimental Oncology (M.R.), European Institute of Oncology IRCSS, Milan.

Andrea Taddei (A)

Benevolent AI, London, United Kingdom (A.T.).

Maria Grazia Lampugnani (MG)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).
Mario Negri Institute for Pharmacological Research, Milan (M.G.L.).

Federica Pisati (F)

Cogentech SRL Benefit Corporation, Milan (F.P.).

Matteo Malinverno (M)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Emanuele Martini (E)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Ilaria Costa (I)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Michela Lupia (M)

Unit of Gynaecological Oncology Research (M.L., U.C.), European Institute of Oncology IRCSS, Milan.

Ugo Cavallaro (U)

Unit of Gynaecological Oncology Research (M.L., U.C.), European Institute of Oncology IRCSS, Milan.

Galina V Beznoussenko (GV)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Alexander A Mironov (AA)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Bethania Fernandes (B)

Pathology Unit, Humanitas Clinical and Research Centre, Rozzano, Milan (B.F., N.R.).

Noemi Rudini (N)

Pathology Unit, Humanitas Clinical and Research Centre, Rozzano, Milan (B.F., N.R.).

Elisabetta Dejana (E)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).
Oncology and Haemato-Oncology, School of Medicine, University of Milan (E.D.).
Immunology, Genetics and Pathology, Uppsala University, Sweden (E.D.).

Monica Giannotta (M)

From the FIRC Institute of Molecular Oncology, Milan, Italy (N.K., L.F., A.A.S., C.M., M.G.L., M.M., E.M., I.C., G.V.B., A.A.M., E.D., M.G.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH